Table 1.
Subject characteristics
| Characteristics | Train/validation CGMH (n = 176) | Internal testing CGMH (n = 326) | External testing FAH-XJU (n = 82) | External testing FAH-ZU (n = 447) | External testing GPH (n = 50) | External testing HHA-FU (n = 195) | External testing SMU (n = 227) |
|---|---|---|---|---|---|---|---|
| Sex | |||||||
| Male | 160 (91%) | 284 (87%) | 65 (79%) | 321 (72%) | 33 (66%) | 145 (75%) | 161 (71%) |
| Female | 16 (9%) | 42 (13%) | 17 (21%) | 126 (28%) | 17 (34%) | 50 (25%) | 66 (29%) |
| Diagnostic age | 54 [48–61] | 54 [49–62] | 57 [49–66] | 57 [50–65] | 58 [49–70] | 56 [47–65] | 50 [42–57] |
| Tumor site | |||||||
| Nasopharynx | 7 (4%) | 90 (28%) | 16 (19%) | 349 (78%) | 2 (4%) | 94 (48%) | 199 (88%) |
| Oropharynx | 140 (80%) | 86 (26%) | 20 (24%) | 26 (6%) | — | 2 (1%) | 9 (4%) |
| Hypopharynx | 16 (9%) | 115 (35%) | — | 16 (4%) | — | 8 (4%) | 3 (1%) |
| Larynx | 2 (1%) | 12 (4%) | 38 (47%) | 11 (2%) | 9 (18%) | 25 (13%) | 4 (2%) |
| Oral Cavity | 9 (5%) | 15 (5%) | 9 (10%) | 39 (9%) | 3 (6%) | 2 (1%) | 5 (2%) |
| Salivary gland | — | — | — | — | 4 (8%) | 4 (2%) | 3 (1%) |
| Others | 2 (1%) | 8 (2%) | — | 6 (1%) | 32 (64%) | 60 (31%) | 4 (2%) |
| Clinical T-stage | |||||||
| cT1 | 23 (13%) | 50 (15%) | 10 (12%) | 55 (12%) | 12 (24%) | 14 (7%) | 20 (9%) |
| cT2 | 64 (36%) | 82 (25%) | 33 (41%) | 181 (41%) | 18 (36%) | 64 (33%) | 54 (24%) |
| cT3 | 42 (24%) | 81 (25%) | 25 (30%) | 122 (27%) | 12 (24%) | 35 (18%) | 101 (44%) |
| cT4 | 47 (27%) | 113 (35%) | 14 (17%) | 89 (20%) | 8 (16%) | 82 (42%) | 52 (23%) |
| OAR types annotated | 42 | 42 | 13 | 13 | 17 | 13 | 25 |
CGMH Chang Gung Memorial Hospital, FAH-XJU First Affiliated Hospital of Xi'an Jiaotong University, FAH-ZU First Affiliated Hospital of Zhejiang University, GPH Gansu Provincial Hospital, HHA-FU Huadong Hospital Affiliated of Fudan University, SMU Southern Medical University.
Note: others of tumor sites include tumors located in the brain, nasal cavity, or lymph node metastasis.